NEUTRAL / CAUTIOUS Nasdaq-100 futures rebound 0.52% and Asia is mostly firmer, but Monday's broad growth selloff, 4.70% 10-year yield and Iran/trade risk prevent a clean risk-on call.
Generated 08:30:43 CEST (Europe/Rome) · Data cutoff 08:31 CEST / 06:31 UTC. U.S. cash figures are Monday closes; futures, rates, dollar and commodities are overnight observations near cutoff. Asian quotes are late session and may not be official final closes. 08:30 Italy precedes the European cash open and many U.S. releases.
NQ futures lead at +0.52% after the Nasdaq cash index lost 0.76% Monday. This is a repair attempt, not yet a reversal: require positive opening breadth and semiconductors holding the first-hour range. CNBC NQ
Washington announced a secondary-sanctions strategy aimed at Iran's trade partners, while a separate U.S.–Canada auto-tariff threat targets 50% from Jan. 1, 2027. WTI's overnight decline says the market is not pricing an immediate supply shock, but headline gaps remain possible. Iran · Canada
BEA schedules Q2 GDP second estimate and July income/outlays for 08:30 ET; NVIDIA reports after the close. Nasdaq now shows a $2.09 EPS forecast from 12 estimates—vendor consensus, not company guidance. BEA · Nasdaq API
Risk class: large-cap, high-valuation AI networking · Classification: relative-strength long only on confirmation · Horizons: day trade; 1–4 week swing after NVIDIA; 3–12+ months only with valuation/FCF support. Direction uncertain.
Thesis/catalyst: Monday's −0.27% outperformance versus Nasdaq −0.76% and AI hardware peers suggests sponsorship. NVIDIA's report is the near catalyst for Ethernet/networking demand expectations.
Evidence / counterargument: $188.15 close and high volume support attention. Counter: one-day relative strength is weak evidence; customer concentration, competition, rates and a negative AI-capex read-through can reverse it.
Entry/confirmation: reclaim Monday's $190.25 high with positive semiconductor breadth; day traders can instead require an opening-range hold. Invalidation/downside: close below $186; next reference $180. Do not carry oversized exposure through NVIDIA. Nasdaq
Risk class: small/high-beta speculative growth; squeeze and dilution prone · Classification: avoid chase; bearish only after failed rebound · Horizons: day trade; 1–4 week avoid/observe; no 3–12+ month entry absent stronger commercial economics. Direction uncertain.
Thesis/catalyst: another 7.6%–8.6% down day shows unstable momentum and weak valuation anchors. High yields remain a headwind.
Evidence / counterargument: exchange-linked Nasdaq data and SEC filings verify price and disclosure context. Counter: contracts, government support and technical breakthroughs can trigger violent rallies and real option value.
Entry/confirmation: no blind short; only failed rebounds followed by breaks below Monday closes—IONQ $41.06, RGTI $16.37, QBTS $18.68, QUBT $8.24. Invalidation: sustained reclaim of Monday highs: $43.55/$17.50/$19.95/$8.72. Short loss is unlimited; availability/fees unknown. Nasdaq
Risk class: mega-cap earnings-gap / high-duration · Classification: avoid fresh swing; tactical bearish only on failed bounce · Horizons: day trade; 1–4 weeks after earnings; 3–12+ month thesis valuation and guidance dependent.
Thesis/catalyst: Monday's −2.91% close at $208.48 confirms pre-event de-risking. Wednesday's macro plus earnings creates two-way gap risk too large for a high-confidence directional call.
Evidence / counterargument: Nasdaq confirms the price, 135.2M volume and Aug. 26 earnings date. Counter: profitable scale, pricing power and a strong guide can produce a sharp upside gap.
Entry/confirmation: no pre-event swing. Tactical bearish only on a failed rebound below $210 with weak semis; close before results. Invalidation: reclaim $215.60; downside references $207/$200. Short losses unlimited; no borrow claim. Nasdaq
No second/third bullish or third bearish idea: the futures bounce is unconfirmed and Wednesday's event concentration makes additional calls lower quality.
| Ticker / risk class | Classification & horizon | Thesis / catalyst / counterargument | Confirmation / invalidation / key risks | C / R / O |
|---|---|---|---|---|
| Watch VRT NYSE · high-beta AI power/cooling | Repair only. Day: opening range. Swing: post-NVDA. Long term: fundamentals/valuation. | Monday −2.66% to $254.97 invalidated yesterday's setup; NVIDIA can validate infrastructure demand. Counter: valuation, rates, project timing. | Reclaim $258.30 then $262; invalidate below $249.97. Earnings read-through and gap risk. | 70 / 84 / 59 |
| Watch AVGO Nasdaq · mega-cap AI/custom silicon | Repair watch. Day/swing only after reclaim; 3–12 months after Sep. 2 earnings evidence. | Monday −2.63% to $358.76; NVIDIA and its Sep. 2 earnings are catalysts. Counter: customer concentration, leverage, valuation. | Reclaim $366.20/$368.45; invalidate below $358 then $350. Event gaps. | 68 / 82 / 60 |
| Watch NVO / LLY NYSE · large-cap peptide leaders | Relative-value watch. No forced day trade; swing after stabilization; long-term on pipeline/valuation. | NVO +0.39% resisted while LLY −0.67%. Retatrutide program advanced. Counter: pricing, reimbursement, supply, safety and competition. | NVO hold $46.50/reclaim $47.30; LLY reclaim $1,262. Invalidate below $46.50/$1,230. Binary regulatory and valuation risk. | 74 / 72 / 60 |
| Watch VKTX Nasdaq · small-cap clinical biotech | Speculative repair only. Day/swing; no core long without clinical de-risking. | Monday −1.95% to $33.23 invalidated the prior setup. Pipeline optionality remains, but no fresh pivotal evidence was verified. | Reclaim $33.77 then $34.36; invalidate below $32.61. Trial, safety, cash burn, dilution and binary gaps. | 57 / 92 / 52 |
| Watch MRVL Nasdaq · high-beta networking/custom silicon | Earnings watch only. Day: Aug. 27 reaction; swing/long term after guidance. | Monday −3.27% to $229.29. Nasdaq lists Aug. 27 after hours, $0.65 forecast from 8 estimates. Counter: consensus uncertainty and gap risk. | No pre-event call. Confirm guidance plus post-gap hold above $231.70; risk below $220.42. Customer concentration, rates. | 64 / 90 / 57 |
C / R / O = Thesis Confidence / Risk / Opportunity. Confidence measures evidence quality, not outcome probability.
Bias: neutral until the first 30–60 minutes. ANET is the only conditional long above $190.25 with breadth. Avoid blind quantum shorts and pre-earnings NVDA swings.
Biggest risk: policy headline or futures-fade gap. Invalidation: NQ loses overnight low 29,017 and 10Y rises; bullish bias strengthens only if NQ holds above 29,266 with broad participation.
Bias: light size until Wednesday's macro/NVIDIA sequence. Prefer post-event bases over prediction.
Biggest risk: yields and AI guidance reprice together. Invalidation: sustained S&P recovery above 7,700 with improving breadth reduces caution; a break below Monday's 7,638 low worsens it.
Bias: prefer profitable, cash-generative infrastructure; demand commercial economics for quantum and clinical/regulatory evidence for biotech. Keep speculative sleeves small.
Biggest risk: peak expectations under high real/nominal yields. Invalidation: durable FCF acceleration, structurally lower long yields, or material clinical/commercial de-risking.